ArQule

  • ArQule announces tivantinib meets primary endpoint

    ArQule announces tivantinib meets primary endpoint, significantly extending time to progression in Phase 2 trial in second-line hepatocellular carcinoma.

    ArQule | 13 March 2012

  • Daiichi Sankyo to license ARQ 092 from ArQule

    ArQule and Daiichi Sankyo announced the execution of a license agreement for the development of a new AKT inhibitor called ARQ 092, the first compound to emerge from the companies' November 2008 agreement to collaborate on research utilizing the AKIP (ArQule Kinase Inhibitor Platform) technology to generate novel, selective and potent small molecule kinase inhibitors. Under the license agreement, Daiichi Sankyo will obtain exclusive rights for development, manufacturing and marketing of ARQ 092 on a worldwide basis.

    ArQule | 01 December 2011

  • Oncology drug discovery collaboration

    ArQule and Daiichi Sankyo are expanding their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, with an option for a…

    ArQule | 12 November 2010